Cognex (Tacrine) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 26, 2012

Cognex

Alzheimer's Disease »

What is dementia?

Dementia is a syndrome characterized by:

impairment in memory,

impairment in another area of thinking such as the ability to organize thoughts and reason, the ability to use language, or the ability to see accurately the visual world (not because of eye disease), and

these impairments are severe enough to cause a decline in the patient's usual level of functioning.

Although some kinds of memory loss are normal parts of aging, the changes due to aging are not severe enough to interfere with the level of function. Many different diseases can cause dementia, but Alzheimer's disease is by far the most common cause for dementia in the United States and in most countries in the world.

What is Alzheimer's disease?

Alzheimer's disease (AD) is a slowly progressive disease of the brain that is characterized by impairment of memory and eventually by dist...

Read the Alzheimer's Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Cognex

Dementia Slideshow Pictures

Alzheimer's Disease Slideshow Pictures

Take the Alzheimer's Quiz

font size

OVERDOSE

As in any case of overdose, general supportive measures should be utilized. Overdosage with cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

Tertiary anticholinergics such as atropine may be used as an antidote for Cognex® (tacrine) overdosage. Intravenous atropine sulfate titrated to effect is recommended: in adults, nitial dose of 1.0 to 2.0 mg IV with subsequent doses based on clinical response. In children, the usual IM or IV dose is 0.05 mg/kg, repeated every 10-30 minutes until muscarinic signs and symptoms subside and repeated if they reappear. Atypical increases in blood pressure and heart rate have been reported with other cholinomimetics when coadministered with quaternary anticholinergics such as glycopyrrolate.

It is not known whether Cognex® (tacrine) or its metabolites can be eliminated by dialysis (hemodialysis, peritoneal dialysis, or hemofiltration).

The estimated median lethal dose of tacrine following a single oral dose in rats is 40 mg/kg, or approximately 12 times the maximum recommended human dose of 160 mg/day. Dose-related signs of cholinergic stimulation were observed in animals and included vomiting, diarrhea, salivation, lacrimation, ataxia, convulsions, tremor, and stereotypic head and body movements.

CONTRAINDICATIONS

Cognex® (tacrine) is contraindicated in patients with known hypersensitivity to tacrine or acridine derivatives.

Cognex® (tacrine) is contraindicated in patients previously treated with Cognex® (tacrine) who developed treatment-associated jaundice; a serum bilirubin > 3 mg/dL; and/or those exhibiting clinical signs or symptoms of hypersensitivity (eg, rash or fever) in association with ALT/SGPT elevations.

Last reviewed on RxList: 6/24/2008
This monograph has been modified to include the generic and brand name in many instances.